GlaxoSmithKline's Covid-19 Treatment Use Limited by FDA
February 24 2022 - 5:44AM
Dow Jones News
By Joe Hoppe
GlaxoSmithKline PLC's monoclonal antibody treatment for the
coronavirus, sotrovimab, has been limited in use by the U.S. Food
and Drug Administration, the federal agency said late
Wednesday.
The pharmaceutical giant's product shouldn't be used to treat
patients with mild-to-moderate infections in places where the
disease is likely to have been caused by a variant that isn't
susceptible to the drug, the FDA said.
GlaxoSmithKline's partner Vir Biotechnology Inc. has previously
said sotrovimab retains its neutralizing of the activity of the
emerging BA.2 form of the Omicron variant of the coronavirus.
The FDA said it will monitor conditions to determine whether the
drug should be used in certain geographic regions.
Shares at 1011 GMT were down 4.2 pence, or 0.3%, at 1,545.8
pence.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
February 24, 2022 05:29 ET (10:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
